Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 3/20 | 0.50 |
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.48 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.45 |
| ▸ | TACR3 | P29371 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3455507 | 0.81 | MEN1 (0.62) | MEN1ALDH1A1MAPK1KMT2AKCNA5 | |
| SCHEMBL23136225 | 0.78 | MAPK8 (0.56) | ALDH1A1GAAMAPTMAPK8 | |
| SCHEMBL17137884 | 0.74 | ALDH1A1 (0.58) | MEN1ALDH1A1MAPK1KMT2AGAA | |
| SCHEMBL7648242 | 0.73 | ACKR3 (0.51) | MEN1ALDH1A1KMT2AGAAMAPT | |
| SCHEMBL5948114 | 0.73 | MAPT (0.66) | MEN1ALDH1A1MAPK1KMT2AGAA | |
| SCHEMBL16462431 | 0.73 | NPC1 (0.49) | MEN1ALDH1A1MAPK1KMT2AMAPT | |
| SCHEMBL3373770 | 0.72 | KMT2A (0.57) | MEN1ALDH1A1MAPK1KMT2A | |
| SCHEMBL7896983 | 0.72 | SLC6A9 (0.74) | SLC6A9 | |
| SCHEMBL25447772 | 0.72 | MAPK8 (0.52) | ALDH1A1KMT2AGAAMAPTMAPK8 | |
| SCHEMBL329764 | 0.71 | ALDH1A1 (0.57) | MEN1ALDH1A1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050234106-A1 | Cycloalkyl inhibitors of potassium channel function | LLOYD JOHN | 2005-10-20 | — | — | US | disclosed |
| EP-1507504-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | Bristol-Myers Squibb Company (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20040072880-A1 | Cycloalkyl inhibitors of potassium channel function | ICAGEN, INC. | 2004-04-15 | — | — | US | disclosed |
| WO-2003063797-A2 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234106-A1 | Cycloalkyl inhibitors of potassium channel function | KCNJ2, KCNN3, KCNQ5 | MEN1 4430/4885ALDH1A1 4075/4885MAPK1 1357/4885 |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | MEN1 4430/4885ALDH1A1 4075/4885MAPK1 1357/4885 |
| US-20040072880-A1 | Cycloalkyl inhibitors of potassium channel function | KCNN1, KCNN2, KCNH2 | MEN1 4044/4885ALDH1A1 2859/4885MAPK1 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.